Smruthi Organics Ltd receives Attestation of Inspection from EDQM

Smruthi Organics Limited has received an "Attestation of Inspection" from the European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, following the inspection conducted at its flagship API manufacturing facility, Unit II in Solapur, Maharashtra, from 27 August 2025 to 29 August 2025.

The attestation confirms that the facility operates in compliance with the application submitted to EDQM for Amlodipine Besilate and meets the applicable European Good Manufacturing Practice (EU GMP) requirements under the CEP and European regulatory framework.

This represents successful closure of the EDQM inspection process.

The Company believes this development significantly strengthens its position in regulated European and allied markets and enhances its credibility with global customers. The positive inspection outcome is expected to support business expansion, improve customer confidence, and create additional opportunities in regulated export markets.

The formal Certificate of Suitability (CEP) is currently under final administrative processing by EDQM. The Company will update the exchanges upon receipt of the СЕР.

Smruthi Organics Limited remains committed to sustained regulatory excellence, quality leadership, and long-term value creation for its stakeholders.

Shares of Smruthi Organics Ltd was last trading in BSE at Rs. 110.65 as compared to the previous close of Rs. 112.05. The total number of shares traded during the day was 2046 in over 36 trades.

The stock hit an intraday high of Rs. 112.90 and intraday low of 108.25. The net turnover during the day was Rs. 224217.00.

Source : Equity Bulls

Keywords

SmruthiOrganics INE172E01011 Pharmaceuticals EDQM